GG 1978 SICAF SIF S.A. - GG Strategic
CIK: 0001814890
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 267,815 | $11.0M | 9/20/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 232,185 | $9.6M | 9/19/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 154,986 | $6.5M | 9/16/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 248,006 | $10.6M | 9/8/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 250,000 | $10.6M | 9/7/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,994 | $88K | 8/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.